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Objectives. We sought to determine the effect of high dose
intravenous bolus heparin on early coronary patency before
primary angioplasty.
Background. Early coronary angiography after thrombolysis
for acute myocardial infarction has shown better patency when
intravenous heparin is used as an adjunct. The present study
explores whether heparin alone can induce reperfusion.
Methods. In the Heparin in Early Patency (HEAP) pilot study,
108 patients with signs and symptoms of acute myocardial infarc-
tion <6 h eligible for primary angioplasty received a single
intravenous bolus of 300 U/kg of heparin together with aspirin
(160 mg chewed) in the emergency room. The median dose of
bolus heparin given was 27,000 U. Patency of the infarct-related
artery (IRA) was assessed by coronary angiography at a median of
85 min after the heparin bolus.
Results. In 55 patients (51%, 95% confidence interval 38% to
64%), Thrombolysis in Myocardial Infarction (TIMI) flow grade 2
or 3 was observed at 90 min: TIMI flow grade 3 in 33 patients
(31%); TIMI flow grade 2 in 22 (20%). Thirty-two (64%) of 50
patients with symptoms <22 h had TIMI flow grade 2 or 3 versus
23 (40%) of 58 patients with symptoms >2 h (p 5 0.02). No
significant bleeding was seen. Two patients (2%) died in the
hospital. The patency results obtained in patients treated with the
high dose bolus heparin were compared with those in 108 patients
from a large primary angioplasty database, who were treated with
standard therapy, including aspirin but not intravenous heparin,
and were matched for clinical and angiographic characteristics
with the HEAP pilot study patients. They showed an 18% patency
rate (p < 0.001) of the IRA (TIMI flow grade 3 in 9%, TIMI flow
grade 2 in 9%) before primary angioplasty.
Conclusions. Early therapy with high dose heparin is associated
with full coronary reperfusion in a considerable number of
patients with acute myocardial infarction, especially in those
treated early (<2 h). This simple, inexpensive, probably safe and
easily antagonizable treatment may be an attractive first treat-
ment of acute myocardial infarction both before and during the
hospital stay in conjunction with primary angioplasty.
(J Am Coll Cardiol 1998;31:289–93)
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Reperfusion therapy has become the cornerstone in the early
treatment of acute myocardial infarction. Both pharmacologic
therapy with thrombolysis (1,2) and primary angioplasty (3,4)
can be used to achieve reperfusion of the infarct-related
coronary artery. Thrombolysis has the disadvantages of bleed-
ing complications, thrombin generation and partial efficacy,
whereas primary angioplasty is successful in .90% of patients
but has logistic limitations, including the inherent delay (“door
to balloon time”) during which no specific reperfusion therapy
can be instituted. However, the introduction of primary angio-
plasty as an accepted therapy makes the testing of new
reperfusion strategies or their adjuncts possible.
For .30 years, the role of heparin in the treatment of acute
myocardial infarction has been controversial with regard to
safety and efficacy. There is a large interindividual dose-
response variability for heparin, making the efficacy of heparin
unpredictable. Since the introduction of thrombolytic therapy
for acute myocardial infarction, the heparin controversy has
persisted until the publication of the Global Utilization of
Streptokinase and TPA for Occluded Coronary Arteries
(GUSTO) trial results (1,2). Heparin, 5,000 U intravenously,
followed by infusion at an activated partial thromboplastin
time (APTT) between 60 and 85 s in conjunction with front-
loaded tissue-type plasminogen activator (t-PA) resulted in the
highest 90-min patency rate and subsequently the lowest mortality
rate. Although the addition of intravenous heparin to streptoki-
nase resulted in a trend toward improved patency, it did not lead
to better survival than that with subcutaneous heparin (2).
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Compared with subcutaneous heparin, intravenous heparin did
not prevent reocclusion in the GUSTO and other trials (5),
suggesting that intravenous heparin facilitates early reperfu-
sion rather than preventing reocclusion.
High dose heparin alone may induce lysis of experimental
carotid artery thrombi, albeit in a lower percentage of patients
than t-PA (6). Unfractionated heparin infusion can also en-
hance fibrinolysis in healthy volunteers (7).
In the present report we describe our initial experience with
high dose bolus heparin as a first treatment in patients with an
acute transmural myocardial infarction eligible for primary
angioplasty treated with aspirin but not with thrombolysis. A
heparin dose of 300 U/kg was chosen on the basis of the
experience of cardiac surgeons. This high dose has been used
for years before cardiopulmonary bypass. In the present study,
the infarct-related artery patency before primary angioplasty
was used to test the efficacy of high dose bolus heparin given at
hospital admission together with aspirin. The results of this
clinical trial were compared with those in a matched control
group from a large primary angioplasty data base.
Methods
Patients. The Heparin in Early Patency (HEAP) protocol
was approved by the ethical review committees of the four
participating hospitals (North Colorado Medical Center, Gree-
ley, Colorado; and Free University Hospital, Amsterdam;
Weezenlanden Hospital, Zwolle; and University Hospital,
Nijmegen, The Netherlands).
To study the objective, a pilot trial consisting of 100 patients
was designed. Given the reported spontaneous reperfusion rate of
10% to 20%, a reliable patency rate with 100 patients treated with
high dose bolus heparin could be expected in 100 patients.
Patients #75 years old with symptoms suggestive of an
acute myocardial infarction #6 h in duration and electrocar-
diographic (ECG) abnormalities of $2-mm ST segment ele-
vation in two or more contiguous leads were eligible for entry
in the study. Patients with contraindications to thrombolysis,
heparin or aspirin or those unable to undergo cardiac cathe-
terization were excluded, as were those in cardiogenic shock.
After informed consent was obtained for the experimental
therapy and the subsequent invasive procedure, 160 mg of
aspirin was chewed. Immediately thereafter a single intrave-
nous bolus of 300 U/kg body weight of heparin was adminis-
tered. No thrombolytic agent was given. Intravenous beta-
blockade or nitrates, or both, were used as clinically indicated.
Coronary angiography and rescue procedures. Coronary
angiography was performed as soon as possible after bolus
heparin therapy. Patency of the infarct-related artery (IRA)
was scored according to Thrombolysis in Myocardial Infarction
(TIMI) flow grade (8) by two independent experienced angiog-
raphers (G.V., F.Z.) in the angiographic core laboratory. In
case of disagreement, the opinion of a third angiographer was
decisive. Angiography was repeated at hospital discharge at
two of the participating centers. During both procedures, left
ventriculography was performed in the right anterior oblique
view to calculate left ventricular ejection fraction.
If IRA patency at first angiography was TIMI flow grade 0
to 1 or less, primary angioplasty was performed. If angioplasty
was not an option, emergent coronary artery bypass graft
surgery was performed, or intracoronary streptokinase was
delivered at a rate of 4,000 U/min for a maximum of 1 h. If
infarct-related artery patency was TIMI flow grade 2 or 3, the
decision to perform primary angioplasty was left to the discre-
tion of the attending operator.
Follow-up treatment. Heparin therapy was started in all
patients after the APTT had reached 2.0 to 2.5 times the
control value. Aspirin, 80 mg daily, was given, as was heparin
at an APTT of 2.0 to 2.5 times the control value for 48 h.
Beta-blockade was continued unless contraindicated, and
angiotensin-converting enzyme blockade was initiated when
indicated. Revascularization was performed on clinical not
angiographic grounds, except for left main coronary artery
disease.
Control group. To compare the patency data obtained in
the HEAP pilot study, angiograms of selected patients from
the large Zwolle primary angioplasty data base, which contains
the data of .800 patients, were studied. These patients had
undergone primary angioplasty without pretreatment with
intravenous heparin in the emergency room. Patients were
matched for age, gender, IRA, time to admission and door to
balloon time with the HEAP pilot study patients. Patency of
the IRA before angioplasty was scored as previously described
in the core laboratory by the same angiographers, who were
unaware of the initial treatment.
Statistical analysis. The statistical methods used in this
analysis are given where appropriate.
Results
Patients. Between November 1993 and June 1996, 108
patients were enrolled in the HEAP pilot study, not 100
patients as originally planned (see Methods). The baseline
characteristics of the patients are shown in Table 1. Doses of
bolus heparin given varied from 10,000 to 40,000 U (median
27,000). The bolus injection was completed in 106 (98%) of
108 patients. In one patient, heparin infusion was discontinued
after 10,000 U, when hypotension occurred, which later proved
to be cardiogenic shock. Another patient refused further
therapy after 10,000 U of intravenous heparin had been given
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APTT 5 activated partial thromboplastin time
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HEAP 5 Heparin in Early Patency
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ISIS 5 International Study on Infarct Survival
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because of complete relief of pain. Both patients proved to
have an open IRA.
Patency at 90 min. The median time interval between
bolus heparin therapy and coronary angiography was 85 min
(range 30 to 120 min). In 55 patients (51%, 95% confidence
interval 38% to 64%), TIMI flow grade 2 or 3 was seen: TIMI
flow grade 3 in 33 patients (31%); TIMI flow grade 2 in 22
(20%). Of 50 patients with symptoms #2 h in duration, 32
(64%) had TIMI flow grade 3 (n 5 21) or 2 (n 5 11) versus 23
(40%) of 58 patients (12 with TIMI flow grade 3, 11 with TIMI
flow grade 2) with symptoms $2 h in duration (p 5 0.02,
chi-square test) (Fig. 1). There were no significant differences
in age (59 6 9 years [mean 6 SD] for TIMI flow grade 0 or 1
vs. 60 6 10 years for TIMI flow grade 2 or 3), gender or receipt
of beta-adrenergic blocking agents (43% and 47%, respec-
tively) and nitrates (94% and 100%, respectively). The 90-min
patency rates are shown in Table 2.
Rescue procedures. The 53 patients with TIMI flow grade
0 or 1 were eligible for rescue procedures. In 47 patients
primary angioplasty was performed and was successful in all
but two. In two other patients, balloon angioplasty was not
considered feasible: Intracoronary streptokinase was given
successfully in one patient, and coronary atherectomy was
performed in the other, resulting in full reperfusion. In one
other patient, emergent coronary artery bypass graft surgery
was carried out successfully. Finally, in three patients with
failed reperfusion after high dose bolus heparin, the attending
physician decided that a rescue procedure was not indicated.
These patients had distal coronary occlusion. Thus, the overall
reperfusion success rate was 95% (103 of 108).
In 15 of 20 patients with TIMI flow grade 2, the operator
decided to perform primary angioplasty, which was successful
in 13. In one patient, nonocclusive coronary dissection oc-
curred, followed by elective coronary surgery, and one patient
with failed angioplasty underwent rescue coronary atherec-
tomy.
In 22 of 35 patients with TIMI flow grade 3, the operator
decided to perform primary angioplasty, which was successful
in all. Of 13 remaining patients with TIMI flow grade 3, 3
underwent emergent coronary surgery immediately after first
angiography. In the 10 remaining patients, the operator de-
cided not to perform primary angioplasty on angiographic
grounds.
Thus, primary angioplasty was performed in 84 (78%) of
108 patients and not in 34 (22%).
Clinical follow-up. At 90 min after high dose bolus hepa-
rin, the APTT exceeded 120 s in all 106 patients who received
the full dose of heparin. Mean peak creatine kinase was 881
U/liter (range 28 to 5,400). Eight patients (7%) did not have an
infarction by elevated enzyme levels (less than twice the upper
limit of creatine kinase). No cerebral bleeding was seen nor
was any bleeding leading to blood transfusion observed during
the entire hospital phase. Two patients (2%) died: one after
elective coronary surgery 9 days after hospital admission; one
after recurrent myocardial infarction 3 days after admission.
Repeat angioplasty was necessary in seven patients (7%) and
elective coronary surgery in seven (7%) during the hospital
stay.
Of 29 patients undergoing predischarge coronary angiogra-
phy, 25 patients (86%) had TIMI flow grade 3, and 3 (10%)
Figure 1. Patency of the IRA (TIMI flow grade 2 [open areas] or 3
[solid areas]) 90 min after high dose bolus heparin in the HEAP pilot
study in patients with symptoms #2 h versus those with symptoms
.2 h.
Table 1. Baseline Characteristics of Heparin and Early Patency Pilot






Median age (yr) 59 59
Range 34–75 29–75
Men 84% 84%
Median time from 1st sx to tx (h) 2.2 2.2
Range 0.3–6.0 0.8–6.0
Anterior infarction (no. of pts) 64 64
Inferior infarction (no. of pts) 44 44
HEAP 5 Heparin in Early Patency; sx 5 symptoms; tx 5 treatment.
Table 2. Patency at 90 Minutes by Coronary Artery: Heparin in
Early Patency Pilot Study
IRA
TIMI Flow Grade
Total0 or 1 2 or 3
LMCA 1 0 1
LAD 29 34 63
LCx 5 6 11
RCA 18 15 33
Total 53 55 108
IRA 5 infarct-related artery; LAD 5 left anterior descending coronary
artery; LCx 5 left circumflex coronary artery; LMCA 5 left main coronary
artery; RCA 5 right coronary artery; TIMI 5 Thrombolysis in Myocardial
Infarction.
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had TIMI flow grade 2. All but three of these patients had
undergone percutaneous transluminal coronary angioplasty
(PTCA) in the acute phase. Reocclusion of initially open
vessels was observed in 1 (4%) of 29 vessels. In 21 patients with
two analyzable left ventricular angiograms and with a persis-
tently open IRA, the left ventricular ejection fraction increased
from 56 6 9% to 59 6 9% (p 5 0.07, Student t test).
Comparison with control patients. The 108 patients from
the Zwolle angioplasty data base were matched for clinical and
angiographic characteristics as described previously, and their
baseline characteristics are shown in Table 1. The control
patients had been treated from February 1993 to April 1996.
As shown in Figure 2, the control patients showed an 18%
patency rate (p , 0.001 vs. HEAP pilot study patients,
chi-square test) of the IRA (TIMI flow grade 3 in 10 patients
[9%], TIMI flow grade 2 in 9 [9%]). Of 42 patients with #2-h
symptom duration, 9 (21%) had TIMI flow grade 3 (n 5 5) or
2 (n 5 4) versus 10 of 66 patients (15%) (5 with TIMI flow
grade 3, 5 with grade 2) with symptoms .2 h (p 5 0.56,
chi-square test).
Discussion
In the HEAP pilot study, a positive influence of high dose
bolus heparin therapy on early IRA patency became apparent.
It is unknown whether this effect approximates the results of
well established intravenous reperfusion strategies such as
streptokinase or t-PA (TIMI flow grade 2 or 3 at 90 min in 57%
and 81% respectively [2]). However, compared with a well
matched primary angioplasty control group not receiving high
dose bolus heparin, the high dose bolus heparin appears to be
superior (51% vs. 18% before angioplasty).
Mode of action of high dose bolus heparin. The exact
mechanism of early patency using high dose bolus heparin is
unknown. High dose heparin achieves lysis of experimental
carotid artery thrombi (6), and a bolus of 5,000 U unfraction-
ated heparin enhances fibrinolysis in healthy individuals (7).
Intravenous heparin together with aspirin may induce coronary
reperfusion by blocking ongoing thrombus formation. In the
Late Assessment of Thrombolytic Efficacy (LATE) trial, intra-
venous heparin, although not randomized, together with aspi-
rin was associated with an 8.7% mortality rate compared with
12.9% for aspirin alone (9). This finding was independent of
the use of thrombolytic therapy. However, in the International
Study on Infarct Survival (ISIS)-2 trial (10), patients random-
ized to aspirin, but not to thrombolysis, additional intravenous
heparin, also not randomized, did not demonstrate improved
survival compared with those without heparin (10.9% and
10.1%, respectively). It should be emphasized that the initial
heparin dose was much lower than that in the present study.
Early treatment with heparin in the HEAP pilot trial
resulted in better reperfusion than later treatment. Appar-
ently, the nature of very fresh clots makes them accessible for
heparin. In general, heparin is ineffective in clot-bound throm-
bin, but this finding may not be true for thrombin in very fresh
arterial thrombi. Recently, preliminary data from a small
randomized trial showed a 50% preangioplasty patency rate in
22 patients with an acute myocardial infarction given high dose
bolus heparin (300 U/kg) at admission versus only 13% in 23
patients given placebo (11). Significant bleeding was not
observed in that trial. Also, other nonthrombolytic strategies
may induce coronary recanalization before primary angioplasty
for acute myocardial infarction. Abciximab, a monoclonal
antibody against the platelet glycoprotein IIb/IIIa receptor,
given to patients in the catheterization laboratory just before
primary angioplasty, proved to induce the process of recanali-
zation within 10 min from the start of therapy (12).
The outcome of the HEAP pilot study may reflect sponta-
neous reperfusion in selected patients, although in the control
group this was limited to ;20%. In the early trials with
intracoronary streptokinase, the administration of heparin and
aspirin before angiography was uncommon, and the rate of
spontaneous coronary reperfusion was found to be 15% to
20% (8,13). This rate is much lower than the early patency rate
observed in the HEAP pilot trial. After publication of the
ISIS-2 trial (10), early administration of aspirin became stan-
dard therapy. Heparin treatment in conjunction with throm-
bolysis has become popular since the introduction of t-PA as a
thrombolytic strategy (2,14–16). Given these established treat-
ment regimens as standard adjuncts to reperfusion therapy, the
true early spontaneous reperfusion rate in modern cardiology
will be difficult to determine and possibly not attainable
secondary to ethical considerations. Finally, it is possible that
the remarkable findings of the HEAP pilot study are attribut-
able to the use of aspirin, but early angiographic patency
studies with aspirin alone do not exist.
Bleeding risk of high dose bolus heparin. The HEAP pilot
study is too small to be conclusive about the safety of a single
Figure 2. Patency of the IRA (TIMI flow grade 2 [open areas] or 3
[solid areas]) 90 min after high dose bolus heparin in the HEAP pilot
study compared with the patency rate before primary angioplasty in
the age- and gender-matched control group not receiving high dose
bolus heparin.
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high dose bolus of heparin in acute myocardial infarction. In
cardiac surgery, from which the heparin dosing in this study
was adopted, cerebral bleeding is very rare. Most strokes after
heart surgery are probably embolic. The incidence of fatal and
major bleeding due to heparin in the absence of thrombolytic
therapy is 0.05% and 0.8%/day of treatment (17). Fatal
bleeding with 2 days of heparin therapy can be expected in
0.1% of patients and major bleeding in 1.6% and is probably
less than that with thrombolysis, where fatal hemorrhagic
stroke occurs in 0.5% of patients (1).
Possible advantages of high dose bolus heparin in acute
myocardial infarction. The advantages of high dose bolus
heparin in the early treatment of acute myocardial infarction
are numerous: 1) The need for primary angioplasty may be
reduced. Only 78% of patients in the HEAP pilot trial had the
procedure compared with .90% for the usual primary PTCA
(3,4). This reduced need may also reduce the cost of primary
angioplasty for acute myocardial infarction, which is currently
similar to (18) or even lower than that for thrombolytic therapy
(19). Furthermore, heparin bolus administration is easy, can be
given before hospital admission and does not necessarily need
ECG guidance. It is inexpensive, and a single dose is probably
safe. In case of bleeding, heparin therapy is easily and defi-
nitely antagonizable. The apparent ability of heparin to induce
reperfusion in some patients raises the possibility that heparin
may significantly augment the efficacy of thrombolytic agents
when it is given in higher doses than have been used previously.
It is intriguing to speculate as to the efficacy of a large dose of
heparin combined with a small dose of a thrombolytic drug.
Finally, in patients ineligible for thrombolysis, high dose bolus
heparin may be an attractive alternative.
Conclusions. In patients with acute transmural myocardial
infarction, early high dose bolus heparin together with aspirin
is associated with a favorable coronary patency rate 90 min
after initiation of therapy. This finding may be of interest for
early prehospital treatment of infarction for patients ineligible
for thrombolytic therapy and for patients awaiting primary
angioplasty of the IRA. The efficacy of this early, single high
dose bolus heparin will be compared with a low dose bolus in
patients with an acute myocardial infarction awaiting primary
angioplasty in a large randomized angiographic trial that has
recently been initiated in The Netherlands.
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